- Home
- IKT vs ARMP Comparison
IKT vs ARMP Comparison
Compare IKT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- ARMP
- Stock Information
- Founded
- IKT 2008
- ARMP N/A
- Country
- IKT United States
- ARMP United States
- Employees
- IKT N/A
- ARMP N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IKT Health Care
- ARMP Health Care
- Exchange
- IKT Nasdaq
- ARMP Nasdaq
- Market Cap
- IKT 111.8M
- ARMP 125.7M
- IPO Year
- IKT 2020
- ARMP N/A
- Fundamental
- Price
- IKT $1.53
- ARMP $7.16
- Analyst Decision
- IKT Hold
- ARMP Strong Buy
- Analyst Count
- IKT 1
- ARMP 1
- Target Price
- IKT N/A
- ARMP $9.00
- AVG Volume (30 Days)
- IKT 109.4K
- ARMP 796.6K
- Earning Date
- IKT 11-14-2025
- ARMP 11-12-2025
- Dividend Yield
- IKT N/A
- ARMP N/A
- EPS Growth
- IKT N/A
- ARMP N/A
- EPS
- IKT N/A
- ARMP N/A
- Revenue
- IKT N/A
- ARMP $5,054,000.00
- Revenue This Year
- IKT N/A
- ARMP $8.43
- Revenue Next Year
- IKT N/A
- ARMP N/A
- P/E Ratio
- IKT N/A
- ARMP N/A
- Revenue Growth
- IKT N/A
- ARMP N/A
- 52 Week Low
- IKT $1.33
- ARMP $0.90
- 52 Week High
- IKT $4.20
- ARMP $16.34
- Technical
- Relative Strength Index (RSI)
- IKT 47.90
- ARMP 71.25
- Support Level
- IKT $1.55
- ARMP $4.65
- Resistance Level
- IKT $1.67
- ARMP $6.93
- Average True Range (ATR)
- IKT 0.13
- ARMP 0.66
- MACD
- IKT 0.01
- ARMP 0.11
- Stochastic Oscillator
- IKT 51.16
- ARMP 98.49
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.